This possibility was first supported by studies showing that NLRC4 inflammasome activation is augmented in HEK293t cells expressing LRRK2 with a kinase gain-of-function mutation (G2019S) (9) and later by studies showing that mice bearing LRRK2 with the same mutation exhibit more severe DSS-colitis than WT mice that is sensitive to LRRK2 kinase inhibition (41). The gene discussed is NLRC4; the disease is colitis.